Open AccessAdverse Effects of Low-Dose Methotrexate
Author(s) -
Daniel H. Solomon,
Robert J. Glynn,
Elizabeth W. Karlson,
Fengxin Lu,
Cassandra Corrigan,
J Colls,
Chang Xu,
Jean MacFadyen,
Medha Barbhaiya,
Nancy Berliner,
Paul F. Dellaripa,
Brendan M. Everett,
Aruna D. Pradhan,
Sarah P. Hammond,
Meredith Murray,
Deepak A. Rao,
Susan Ritter,
Anna Rutherford,
Jeffrey A. Sparks,
Jackie Stratton,
Dong Hyun Suh,
Sara K. Tedeschi,
Kathleen M M Vanni,
Nina P. Paynter,
Paul M. Ridker
Publication year - 2020
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m19-3369
Subject(s) - medicine , placebo , adverse effect , hazard ratio , rheumatoid arthritis , methotrexate , relative risk , body mass index , randomized controlled trial , surgery , confidence interval , alternative medicine , pathology
Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis. Despite extensive clinical use for more than 30 years, few data on adverse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magnitude of risk can be inferred.